Controversy as cancer drug deemed “too expensive” for NHS
A drug that can potentially prolong the lives of patients with advanced liver cancer will not be available to patients on the NHS as the costs are “simply too high”.
NICE, the National Institute for Clinical Excellence, has deemed the £3,000-a-month cost of the drug, Nexavar, could not be borne by the NHS in England, Wales and Northern Ireland. There are as many as 3,000 people diagnosed with liver cancer each year with the prognosis being very poor – only 20 per cent of patients are alive one year after diagnosis, dropping to just 5 per cent after five years.
The decision has, however, outraged both campaigners and medical experts. Campaigner Kate Spall, speaking to Radio 4, spoke of how her 58 year old mother had four extra precious months of life and how it had given her “closure”.
Kate had to fight authorities to start treatment for her mother.
Dr Harpreet Wasan, a Medical Oncologist at Hammersmith Hospital, Imperial College, London, told Medical News Today in September that such a decision would leave doctors with nothing other than supportive and palliative care for such patients. He went on to say that it was akin to:
“Denying them the life-preserving benefits of modern treatments.”
The drug had already been rejected in Scotland with regulatory authorities arguing that the cost to benefit ratio did not warrant its acceptance – this despite evidence showing the drug can potentially prolong survival by up to six months.
The problem for British patients is that the drug is used routinely in other countries and again opens the debate as to how resources are prioritised within the NHS.
-
http://twitter.com/shamikdas/status/5863948931 Shamik Das
-
http://twitter.com/gsdog7/status/5863957355 gsdog7
-
Louis Henry
-
Asif
-
Richard Blogger
-
joe fd
-
http://twitter.com/knowdrugs/status/5889894164 Sunil
-
asif
YouGov Tracker
ToUChstone Economic Tracker
George’s Marvellous Deficit Calculator
Most read this week
- The DWP’s ‘scrounger’ rhetoric is causing real harm
- The government’s drug policy favours dogma over harm reduction
- Climate change sceptics and rural romantics – the Tories are a shambles on renewable energy
- Polls apart? The news for the SNP might not be as good as it looks
- Don’t believe the spin – the health reforms are Cameron’s just as much as Lansley’s
Best of the web
Top issues
Left Foot Facebook
Awards & Rankings
Archive
Tag Cloud
Domestic Progressives
- A Thousand Cuts
- Alastair Campbell
- Andrew Gibson's Blog
- Anthony Painter
- Ayes To The Left
- Blackburn Labour Party
- Chartist
- Conor's Commentary
- Dave's Part
- Diary of a Benefit Scrounger
- Duncan's Economic Blog
- Follow my leaders
- Freemania
- Full Fact
- Go Fourth
- Good Animal / Bad Animal
- Guardian Politics blog
- Harry's Place
- Hopi Sen
- Institute for Government
- Intelligence Squared
- Labour and Capital
- Labour Home
- Labour List
- LabourHome
- Left Central
- Lib-Con Trick
- Liberal Conspiracy
- Liberal Democrat Voice
- LSE politics blog
- Luke's blog
- Mark Thompson Blog
- Matthew Taylor's blog
- Max Atkinson's blog
- Migrants' Rights Network
- New Statesman: free speech
- Next Left
- Nick Pearce
- OurKingdom
- Patrick Bury's blog
- Policy Critical
- Political Reboot
- Political Scrapbook
- Progress
- Red Brick
- RSA Projects
- Runnymede Trust
- Rupa Huq's Blog
- Sadie's Tavern
- Save EMA
- Shamik Das
- Slinger blog
- Tank the Tories
- Tax Research UK
- The Centre Left
- The Green Benches
- The Novocastrian
- This is my truth
- Tim McLoughlin
- Tom Harris MP
- Tom Watson MP
- Touchstone
- Touchstone TUC blog
- Young Fabians Blog







